Tag: Matt Wetzel
Three firms act on BioNTech’s USD950m China partner buyout
A&O Shearman, Goodwin, and Conyers are advising BioNTech on its $950M buyout of a Chinese cancer drug partner to rival Merck
A&O Shearman, Goodwin, and Conyers are advising BioNTech on its $950M buyout of a Chinese cancer drug partner to rival Merck
India’s 2026 model BIT must align investment protection with climate obligations for long-term treaty coherence